Clinical trials of antiangiogenic agents

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 584-589

  Twardowski, Przemyslaw ^a   Gradishar, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BATIMASTAT; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PENTOSAN POLYSULFATE; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; META ANALYSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; RIGOR; TUMOR GROWTH; VOMITING;

EID: 0030772175     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00015     Document Type: Review

References (40)

1. Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992, 267:10931-10934.
2. Folkman J, Klagsburn M: Angiogenic factors. Science 1987, 235:442-447.
3. Dvorak HF, Brown LE, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
4. Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther 1994, 63:265-311.
5. Brooks PC: Role of integrins in angiogenesis. Eur J Cancer 1996, 32A:2423-2429.
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
7. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 1995, 333:1757-1763.
8. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 1996, 275:150-154. An excellent, easy to read review of issues related to introduction of antiangiogenic agents into clinical practice.
9. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990, 348:555-557.
10. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D, Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994, 69:212-216.
11. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994, 34:869-875.
12. Takamiya Y, Freidlander RM, Brem H, Malick A, Martuza RL: Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993, 78:470-476.
13. Tanaka T, Konno H, Matsuda I, Nakamura S, Baba S: Prevention of hepatic metastases of human colon cancer by angiogenesis inhibitor TNP-470. Cancer Res 1995, 55:836-839.
14. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ, Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of cell cycle. Cancer Res 1994, 54:2073-2076.
15. Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y: A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994, 54:3407-3412.
16. Pluda JM, Wyvill K, Figg WD, Whitcup SM, Lietzau J, Saville MW, Cohen R, Feigal E, Parks D, Foli A, Bailey J, Broder S, Yarchoan R: A phase I study of an angiogenesis inhibitor, TNP-470 (AGM-1470), administered to patients with HIV-associated Kaposi's sarcoma [abstract]. Proc Am Soc Clin Oncol 1994, 13:51.
17. Zukiwski J, Gutterman J, Bul C, Sella A, Ellerhorst J, Tu S, Amato R, Figg W, Kilbourn R, Logothelis C: Phase I trial of the angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen independent prostate cancer [abstract]. Proc Am Soc Clin Oncol 1994, 13:252.
18. Levy T, Kudelka A, Verschragen CF, Edwards CL, Freedman RS, Kaplan A, Kieback D, Steger M, Mante R, Gutterman J, Paimsomboon S, Termurungruanglert W, Kavanagh JJ: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix [abstract]. Proc Am Assoc Cancer Res 1996, 37:166.
19. Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol 1990, 1:99-106.
20. Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJR: Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985, 318:6669.
21. Stetler-Stevenson WG, Krutzch HC, Liotta LA: Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989, 264:17374-17378.
22. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cell and tissues. J Biol Chem 1994, 269:9352-9360.
23. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, Summers B: Low molecular weight inhibitors in corneal ulceration. Ann NY Acad Sci 1994, 732:315-323.
24. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR: A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. Cancer Res 1993, 53:2087-2091.
25. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 1996, 32A:2528-2533. This issue gives a comprehensive review of the subject of angiogenesis.
26. Boasberg P, Harbaugh B, Roth B, Eisenberger M, Langleben A, Allen R. Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer [abstract]. Proc Am Soc Clin Oncol 1996, 15:258.
27. Rosemurgy A, Harris J, Langleben A, Casper E, Allen R, Rasmussen H: Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas [abstract]. Proc Am Soc Clin Oncol 1996, 15:207.
28. Gore M, A'Hern R, Stankiewicz M, Slevin M: Tumour marker level during Marimastat therapy. Lancet 1996, 348:263-264.
29. Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G: Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 1997, 15:781-789.
30. Kohn EC, Reed E, Sarosy G, Liotta LA: Clinical investigation of cytostatic calcium influx inhibitor in patients with refractory cancer. Cancer Res 1996, 56:569-573.
31. Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K: A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol 1996, 7:491-496.
32. Zucker MB, Katz IR: Platelet factor 4: production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991, 198:693-702.
33. Kolber DL, Knisely TL, Maione TE: Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995, 87:304-309.
34. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
35. Warren RS, Yuan H, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995, 95:1789-1797.
36. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lare WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328. A classic paper reporting the discovery of one of the newest and most promising cancer-derived inhibitors of angiogenesis.
37. O'Reilly MS, Boehma T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
38. v integrins. Science 1995, 270:1500-1502.
39. 3 antagonists promote regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
40. 3 for angiogenesis. Science 1994, 264:569-571.